Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

Considerations for Prescribing Avacopan for ANCA-Associated Vasculitis

Michele B. Kaufman, PharmD, BCGP  |  October 27, 2021

In early October, the FDA approved avacopan to treat anti-neutrophil cytoplasmic antibody associated vasculitis. Here are insights into the treatment’s risks and considerations.

Filed under:Drug UpdatesVasculitis Tagged with:AAV FocusRheumANCA-Associated Vasculitisanti-neutrophil cytoplasmic antibodies (ANCA)avacopanFDAFDA approvalU.S. Food and Drug Administration (FDA)

Minimizing Disease Activity in Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  October 15, 2021

The use of objective, validated outcome measures to track progress in symptom control for patients with psoriatic arthritis was discussed in a session at the 2019 ACR/ARP Annual Meeting titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater insights into this topic and…

Filed under:ConditionsPsoriatic Arthritis Tagged with:Psoriatic Arthritistapering

Tips for Transitioning Patients from Pediatric to Adult Rheumatology Care

Sarah D. Bayefsky, MD, Kimberly DeQuattro, MD, & Rebecca E. Sadun, MD, PhD  |  October 14, 2021

Approximately 50% of young adult patients with childhood-onset rheumatic diseases become lost to follow-up within the first year of transferring to adult rheumatology care, mirroring the statistics of other subspecialties.1,2 One of the challenges cited most consistently by young adult patients and their families relates to differences between rheumatology care delivery in the pediatric and…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumabPsoriatic Arthritisupadacitinib

Who You Know Matters … But Not with the ARP

Janet L. Poole, PhD, OTR/L, & Christine Stamatos, DNP, ANP-C  |  October 13, 2021

Over the past 16 months, the world has shone a bright light on the importance of diversity, equity and inclusion (DEI). Although the College has been focused on diversity initiatives since 2020, the interprofessional division of the College, the ARP, has recently taken a deeper dive into DEI initiatives in its processes, procedures and volunteering….

Filed under:Interprofessional PerspectiveProfessional Topics Tagged with:Association of Rheumatology Professionals (ARP)DiversityEquityinclusionVolunteering

Regressed germinal center with follicular dendritic cell prominence (star), onion-skinning (blue arrowhead) and increased vascularity (orange arrows) are seen.

Case Report: Is It Castleman Disease, or Castleman-Like?

Philip Chu, MD, RhMSUS, Mithu Maheswaranathan, MD, Jadee L. Neff, MD, PhD, & Rebecca E. Sadun, MD, PhD  |  October 13, 2021

The difference between Castle­man disease and Castleman-like disease may be subtle, but it comes with significant ramifications. Case Presentation This case involves a pregnant 19-year-old woman who presents over multiple hospitalizations with concerns for systemic lupus erythematosus and macrophage activation syndrome. At 36 weeks’ gestation, the patient’s weight had dropped from 215 lbs. to 170…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:case reportCastleman's disease

The Dual-Target Strategy in Rheumatoid Arthritis: Put Patients First

Ricardo J.O. Ferreira, RN, PhD; Leonard H. Calabrese, DO; & José A.P. Da Silva, MD, PhD  |  October 13, 2021

The impressive progress of medical knowledge and technology reinforces our trust in the scientific methodology that made it all possible. However, that progress also creates risks related to the primary goal of medical care: to serve our patients’ interests and enjoyment of life in the best possible way. In this article we present our views…

Filed under:ConditionsPatient PerspectiveRheumatoid ArthritisSpeak Out Rheum Tagged with:Disease Activity Score (DAS)patient centerednessshared decision makingSpeak Out RheumatologyTreat-to-Target

Rohane Hamilton / shutterstock.com

Healthcare Accessibility for People with Rheumatic Disease in New Haven, CT

Vaidehi R. Chowdhary, MD, & Jane E. Dee, BA, MALS  |  October 13, 2021

The COVID-19 pandemic exacerbated wide disparities that exist in the U.S. healthcare system. During the pandemic, the clinical practice in the Section of Rheumatology, Allergy & Immunology at Yale School of Medicine (YSM), New Haven, Conn., rapidly pivoted from face-to-face visits to telehealth to keep our patients and providers safe. Many patients quickly adapted and…

Filed under:Patient PerspectivePractice Support Tagged with:Access to careCOVID-19DisparitiesDr. Lenore Buckleytelehealth

Psoriatic Arthritis Treatment Update

Mary Choy, PharmD, BCGP, FASHP  |  October 13, 2021

About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…

Filed under:Clinical Criteria/GuidelinesConditionsDrug UpdatesPsoriatic Arthritis Tagged with:PsA Resource CenterPsoriatic Arthritis

FDA Approves Avacopan for the Treatment of ANCA-Associated Vasculitis

ChemoCentryx  |  October 8, 2021

On Oct. 8, ChemoCentryx Inc. announced that the U.S. Food & Drug Administration (FDA) has approved avacopan (TAVNEOS), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms…

Filed under:Biologics/DMARDsConditionsDrug UpdatesVasculitis Tagged with:avacopan

A Look Inside the Advocate Experience at Advocates for Arthritis

Eric Dein, MD  |  October 8, 2021

Eric Dein, MD, shared rheumatology perspectives with five congressional offices on Sept. 28 as part of the virtual Hill Day. Read his hour-by-hour account, including staffer education, legislative requests and prior authorization woes.

Filed under:Legislation & Advocacy Tagged with:AdvocacyAdvocates for ArthritisCongressional outreachLegislation & Advocacy

  • « Previous Page
  • 1
  • …
  • 61
  • 62
  • 63
  • 64
  • 65
  • …
  • 245
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences